TIDMFIPP
Frontier IP Group plc
04 April 2019
4 April 2019
Frontier IP Group Plc
("Frontier IP" or the "Group")
Portfolio news - Exscientia reaches first major milestone in GSK
collaboration
Frontier IP, a specialist in commercialising university
intellectual property, is pleased to note yesterday's announcement
from portfolio company Exscientia ("Exscientia" or the "Company) ,
a world leader in artificial intelligence ("AI") drug discovery,
that it has achieved its first major milestone in its collaboration
with GSK.
The Company has delivered a lead molecule targeting chronic
obstructive pulmonary disease (COPD), a progressive lung disease
thought to affect 384 million people globally.
Frontier IP holds a 3.32 per cent stake in the Company.
Exscientia statement in full:
EXSCIENTIA ACHIEVES MOLECULE DISCOVERY MILESTONE AS PART OF GSK
COLLABORATION
Oxford, UK, 3rd April 2019: Exscientia, a world-leading
Artificial Intelligence (AI)-driven drug discovery company -
announces today that it has delivered a highly potent in vivo
active lead molecule, targeting a novel pathway for the treatment
of chronic obstructive pulmonary disease (COPD). By delivering the
candidate, it has reached the first major milestone in its AI-drug
discovery collaboration with GSK.
First selective and potent in vivo active lead molecule to be
delivered under Exscientia's AI collaboration with GlaxoSmithKline
(GSK), targeting a key pathway for the treatment of chronic
obstructive pulmonary disease (COPD).
In vivo active lead milestone discovered with 5 cycles and only
85 compounds tested.
COPD is a progressive lung disease that is thought to affect
around 384 million people worldwide. The burden of COPD is
considerable, both socially and economically, where there is an
urgent and unmet medical need for new and more effective treatment
options.
The molecule was developed through the application of
Exscientia's Centaur Chemist(TM) AI-driven automated drug discovery
platform. This approach has delivered a lead molecule with fewer
compounds synthesised in comparison to conventional industry
benchmarks. The in vivo lead was identified de novo from 85 project
compounds and was synthesised and tested within five iterative
design and screening cycles.
Andy Bell, Chief Research Officer of Exscientia, said: "Our AI
platform and approach have advanced significantly over the past few
years and have been constantly refined and optimised through
real-world projects for our pharma partners. With the productivity
improvements we are now seeing, we believe that our Centaur
ChemistTM approach is proving itself to be the industry's leading
AI-drug discovery platform by achieving far superior results to
what conventional discovery techniques have historically
delivered."
Exscientia entered a strategic AI-drug discovery collaboration
with GSK, with the aim of combining its AI enabled platform with
GSK's long-standing expertise to accelerate the discovery of
quality new molecules. Exscientia is learning from the wealth of
biological and chemistry data resources to drive its AI algorithms
to design novel molecules with exacting product criteria as the
objectives.
Exscientia's approach has already proved itself by delivering
pre-clinical drug candidate molecules in roughly one-quarter of the
time, and at one-quarter of the cost of traditional approaches,
within partnerships with a variety of major pharmaceutical
companies.
Exscientia statement ends
ENQUIRIES
Frontier IP Group Plc T: 020 7332 2338
Neil Crabb, Chief Executive
Andrew Johnson, Communications & Investor M: 07464 546 025
Relations
Company website: www.frontierip.co.uk
Allenby Capital Limited (Nominated Adviser T: 0203 328 5656
and Broker)
Nick Athanas / Nicholas Chambers (Corporate
Finance)
Amrit Nahal (Equity Sales)
Exscientia Limited
Corporate enquiries:
Mark Swindells, Chief Operating Officer
Company website: www.exscientia.co.uk contact@exscientia.co.uk
Twitter: www.twitter.com/exscientialtd
Exscientia media enquiries:
Edelman
exscientia@edelman.com
Marianne Fekene +44(0) 7810298448
Camille Oster +44(0) 7812660934
ABout EXScIENtiA
Exscientia is at the forefront of Artificial Intelligence
(AI)-driven drug discovery and design. By fusing the power of AI
with the discovery experience of seasoned drug hunters, Exscientia
is the first company to automate drug design, surpassing
conventional approaches.
Exscientia's innovative Centaur Chemist(TM) platform enables
breakthrough productivity gains as well as new approaches to
improve drug efficacy. Novel compounds are automatically designed
and prioritised for synthesis by its AI systems, which rapidly
evolve compounds towards the desired candidate criteria for
clinical development.
Exscientia systems learn from both existing data resources and
experimental data from each design cycle. The principle is similar
to how a human would learn, but the AI process is far more
effective at identifying and assimilating multiple subtle and
complex trends to balance potency, selectivity and pharmacokinetic
criteria.
As a result, the AI-driven process is more likely to achieve the
end goal and to do this more rapidly and efficiently than
traditional human endeavour.
Exscientia is collaborating with several leading pharmaceutical
and life sciences companies, including GSK, Sanofi, Evotec, Roche
and Celgene
Exscientia has its headquarters in Oxford, UK with offices in
the UK, USA and Japan. For more information follow us on Linkedin
and Twitter @exscientialtd
ABOUT FRONTIER IP
Frontier IP unites science and commerce by identifying strong
intellectual property and accelerating its development through a
range of commercialisation services. A critical part of the Group's
work is involving relevant industry partners at an early stage of
development to ensure technology meets real world demands and
needs.
The Group looks to build and grow a portfolio of equity stakes
and licence income by taking an active involvement in spin-out
companies, including support for fund raising and collaboration
with relevant industry partners at an early stage of
development.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRADXGDSDDGBGCX
(END) Dow Jones Newswires
April 04, 2019 02:01 ET (06:01 GMT)
Frontier Ip (LSE:FIPP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Frontier Ip (LSE:FIPP)
Historical Stock Chart
From Apr 2023 to Apr 2024